AI
IRLA

ArchPoint Investors’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

ArchPoint Investors’s Portfolio IRLA Stock Details IRLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-15
Closed -$140K – 125
2020
Q1 		$140K Buy
15
+7
+88% +$69.1K 0.06% 93
2019
Q4 		$86K Buy
+8
New +$48.3K 0.03% 104

Other funds holding IRLA

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $31.9B AUM 28.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

ArchPoint Investors's IRLA Position: Q2 2020 in Review

ArchPoint Investors sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2020, closing a stake of 15 shares — an estimated $140K sold.

ArchPoint Investors first reported a position in IRLA in Q4 2019 and held it in 2 quarters. The position peaked at $140K in Q1 2020. 81 funds tracked by Wall St. Rank hold IRLA as of Q2 2020.

  • ArchPoint Investors reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • ArchPoint Investors sold 15 IRulya Therapeutics Inc. Common Stock shares in Q2 2020, an estimated $140K.
  • ArchPoint Investors first reported a position in IRulya Therapeutics Inc. Common Stock in Q4 2019 and held it in 2 quarters.
  • ArchPoint Investors's IRulya Therapeutics Inc. Common Stock position peaked at $140K in Q1 2020.
  • 81 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2020.

Based on ArchPoint Investors's 13F filing for Q2 2020, filed 31 Jul 2020.